Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

v3.8.0.1
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Sales $ 260,960 $ 372,426 $ 570,327 $ 553,900
Cost of Sales 88,357 334,786 177,482 405,680
Gross Margin 172,603 37,640 392,845 148,220
Operating expenses        
Sales and marketing 432,260 377,046 1,313,077 646,509
Research and development 546,350 571,671 1,947,659 1,803,234
General and administrative 783,784 409,669 2,916,917 2,291,136
Share compensation expense (Note 11) 271,001 227,540 1,284,257 651,630
Convertible debt accretion (Note 8) 216,302 0 290,375 0
Amortization (Note 4) 76,985 0 246,920 0
Depreciation (Note 7) 21,234 24,028 69,606 57,781
Total operating expenses 2,347,916 1,609,954 8,068,811 5,450,290
Other expenses (income)        
Foreign Exchange (11,485) 0 102,671 0
Interest expense (Note 8) 416,990 13,808 657,350 23,839
Other income (59) (4,363) 649 (410,877)
Total other expenses (income) 405,446 9,445 760,670 (387,038)
Net loss and comprehensive loss for the period $ (2,580,759) $ (1,581,759) $ (8,436,636) $ (4,915,032)
Loss per share - basic $ (0.03) $ (0.02) $ (0.08) $ (0.05)
Loss per share - diluted $ (0.03) $ (0.02) $ (0.08) $ (0.05)
Weighted average number of shares outstanding - basic 101,794,615 96,362,541 99,335,514 90,286,864
Weighted average number of shares outstanding - diluted 101,794,615 96,362,541 99,335,514 90,286,864